BHCM
COGT icon

Boulder Hill Capital Management’s Cogent Biosciences COGT Stock Holding History

Boulder Hill Capital Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-20,000
Closed -$231K – 146
2022
Q4 		$231K Buy
+20,000
New +$248K 0.19% 106

Other funds holding COGT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Boulder Hill Capital Management's COGT Position: Q1 2023 in Review

Boulder Hill Capital Management sold out of Cogent Biosciences (COGT) in Q1 2023, closing a stake of 20,000 shares — an estimated $231K sold.

Boulder Hill Capital Management first reported a position in COGT in Q4 2022 and held it in 1 quarter. The position peaked at $231K in Q4 2022. 136 funds tracked by Wall St. Rank hold COGT as of Q1 2023.

  • Boulder Hill Capital Management reported no remaining Cogent Biosciences position as of Q1 2023 after selling out during the quarter.
  • Boulder Hill Capital Management sold 20,000 Cogent Biosciences shares in Q1 2023, an estimated $231K.
  • Boulder Hill Capital Management first reported a position in Cogent Biosciences in Q4 2022 and held it in 1 quarter.
  • Boulder Hill Capital Management's Cogent Biosciences position peaked at $231K in Q4 2022.
  • 136 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2023.

Based on Boulder Hill Capital Management's 13F filing for Q1 2023, filed 12 May 2023.